乳腺癌中PRDM2、PRDM5、PRDM16的甲基化检测及临床意义

The methylation detection of PRDM2,PRDM5 and PRDM16 in breast cancer and its clinical significance

目的探讨乳腺癌中PR锌指区域蛋白(PRDM) 2、PRDM5、PRDM16的甲基化检测及临床意义。方法回顾性选取沧州市中心医院收集74例乳腺癌患者组织作为乳腺癌组,另选取62例乳腺良性肿瘤患者组织作为对照组。采用甲基化特异性聚合酶链反应(MSP)检测PRDM2、PRDM5、PRDM16甲基化情况,并分析其与乳腺癌患者临床病理参数的关系,采用COX风险回归对乳腺癌患者无生存进展期(PFS)、总体生存时间(OS)的影响因素进行分析,KaplanMeier法分析患者3年预后情况。结果乳腺癌组织中PRDM2、PRDM5、PRDM16基因启动子甲基化阳性率显著均高于对照组,差异有统计学意义(P <0. 05)。PRDM2、PRDM5启动子甲基化与TNM分期、淋巴结转移、组织学分级相关,PRDM16启动子甲基化与TNM分期、淋巴结转移相关,差异有统计学意义(P <0. 05)。COX风险回归分析显示,PRDM2、PRDM5、PRDM16启动子甲基化是乳腺癌患者PFS、OS的独立影响因素。乳腺癌患者PRDM2、PRDM5、PRDM16启动子甲基化者PFS、OS均低于未甲基化者,差异有统计学意义(P <0. 05)。结论乳腺癌患者PRDM2、PRDM5、PRDM16启动子甲基化在乳腺癌的病情进展中发挥着重要作用,与患者预后相关,可作为其预后检测指标。

Objective The methylation detection of PR zinc finger region protein-2(PRDM2),PRDM5 and PRDM16 in breast cancer and its clinical significance.Methods Seventy-four cases tissues of breast cancer patients in our hospital were selected as breast cancer group,another sixty-two cases of patients with benign breast tumor were selected as control group,methylation specific polymerase chain reaction(MSP)was used to detect the methylation of PRDM2,PRDM5 and PRDM16,its relationship with clinicopathological parameters in in breast cancer patients was analyzed,COX risk regression was used to analyze the progression free survival(PFS)and overall survival time(OS)of breast cancer patients,Kaplan-Meier analyzed the prognosis after three years.Results The positive rates of PRDM2,PRDM5 and PRDM16 gene promoter methylation in breast cancer tissues were significantly higher than those in control group,the difference was statistically significant(P<0.05).Methylation of PRDM2 and PRDM5 promoter were associated with TNM stage,lymph node metastasis and histological grade.The methylation of PRDM16 promoter were associated with TNM stage and lymph node metastasis,and the difference was statistically significant(P<0.05).COX risk regression analysis showed that methylation of PRDM2,PRDM5 and PRDM16 promoter was an independent prognostic factors for PFS and OS in breast cancer patients.The PFS and OS levels in breast cancer patients with PRDM2,PRDM5 and PRDM16 promoter methylation were lower than those with non methylation,and the differences were statistically significant(P<0.05).Conclusion Methylation of PRDM2,PRDM5 and PRDM16 promoter plays an important role in the progression of breast cancer,and is related to the prognosis,and can be used as a prognostic indicator.